C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity
chronic weight management and other weight-related co-morbidities
Investigational medicinal product(s)
PF-08653945
Eligibility
Age group
0-17 years, 65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
AUCinf (if data permit, otherwise AUClast) and Cmax of PF-08653945.
Endpoint detail
Assessment of TEAEs: • Clinical safety laboratory tests, vital signs, 12-lead ECGs, C-SSRS, and PHQ-8.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.